Inmune Bio, Inc. (INMB): Operating Income
-$47.38M
Year ended 2025-12-31
-$20.20M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$47.38M | n/m | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | -$42.63M | n/m | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | -$29.74M | n/m | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | -$25.95M | n/m | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | -$29.15M | n/m | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | -$12.23M | n/m | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | -$7.76M | n/m | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | -$12.44M | n/m | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | -$981.5K | n/a | 2019-03-29, From 2017-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | 2025-12-31 | -$47.38M | n/m |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | -$11.53M | n/m |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | -$11.66M | n/m |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | -$68.78M | n/m |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | -$11.49M | n/m |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | -$13.36M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$77.63M | n/m |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | -$6.14M | n/m |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | -$48.96M | n/m |
Compare INMB, ENTX, AIM, SNTI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗